Skip to main navigation menu Skip to main content Skip to site footer

No. 4 (2024)

NEW MEDICINES

Agomelatine for the Treatment of Generalized Anxiety Disorder

https://doi.org/10.21265/PSYPH.2024.47.73.006

Published 2024-12-30

  • V.E. Medvedev

V.E. Medvedev
Peoples’ Friendship University of Russia (RUDN University)

Abstract

Relevance. Given the prevalence of generalized anxiety disorder (GAD) as well as the functional impairment and maladaptation it causes, there is still a need for further development of methods of long-term effective pharmacotherapy with good tolerability.

This article aimed to analyze literature data on the effectiveness and tolerability of agomelatine in the treatment of GAD.

Materials and methods. Search and analysis of articles published between 2005-2024 years was conducted in PubMed and eLIBRARY databases.

Results. Data from randomized controlled trials and meta-analyses indicate that agomelatine is highly effective for both relief and long-term anti-relapse treatment of GAD. Agomelatine is effective against both groups of anxiety symptoms, especially somatic ones. The highest efficacy of agomelatine was established in a subpopulation of patients with the most severe GAD (HARS ≥ 25, CGI-S ≥ 5). The tolerability of agomelatine is equivalent to that of placebo, without the occurrence of withdrawal symptoms and sexual dysfunction.

Conclusion. The registration of a new indication for agomelatine opens new prospects for the improvement of effectiveness and tolerability of GAD therapy.

Keywords

generalized anxiety disorder, relief, anti-relapse therapy, agomelatin

PDF (Русский)

References

  1. Wittchen H.U., Jacobi F. Size and burden of mental disorders in Europe — a critical review and appraisal of 27 studies // Eur Neuropsychopharmacoi. – 2005. – Vol. 15 (4). – Pp. 357–376. – https://doi.org/10.1016/j.euroneuro.2005.04.012
  2. Kong W., Deng H., Wan J., Zhou Y., Zhou Y., Song B., Wang X. Comparative remission rates and tolerability of drugs for generalised anxiety disorder: A systematic review and network meta-analysis of double-blind randomized controlled trials // Front Pharmacol. – 2020. – Vol. 11. – Art. 580858. – https://doi.org/10.3389/fphar.2020.580858
  3. Yu W., Singh S.S., Calhoun S., Zhang H., Zhao X., Yang F. Generalized anxiety disorder in urban China: Prevalence, awareness, and disease burden // J Affect Disord. – 2018. – Vol. 234. – Pp. 89–96. – https://doi.org/10.1016/j.jad.2018.02.012
  4. Etkin A., Prater K.E., Schatzberg A.F. et al Disrupted amygdalar subregion functional connectivity and evidence of a compensatory network in generalized anxiety disorder // Arch Gen Psychiatry. – 2009. – Vol. 66 (12). – Pp. 1361–1372.
  5. Nutt D., Argyropoulos S., Hood S., Potokar J. Generalized anxiety disorder: A comorbid disease // Eur Neuropsychopharmacoi. – 2006. – Vol. 16, suppl. 2. – Pp. S109–S118.
  6. Roberge P., Normand-Lauziere F., Raymond I. et al. Generalized anxiety disorder in primary care: Mental health services use and treatment adequacy // BMC Earn Pract. – 2015. – Vol. 16. – Art. 146. – https://doi.org/10.1186/s12875-015-0358-y
  7. Mosolov S.N., Martynikhin I.A., Syunyakov T.S., Galankin T.L., Neznanov N.G. Incidence of the diagnosis of anxiety disorders in the Russian Federation: Results of a web-based survey of psychiatrists // Neurology and Therapy. – 2021. – Pp. 1–14. – https://doi.org/10.1007/s40120-021-00277-w
  8. Stein D.J., Ahokas A., Mаrquez M.S., Höschl C., Oh S., Jarema M., Avedisova A.S., Albarran Cr., Olivier V. Agomelatine in generalized anxiety disorder: An active comparator and placebo- controlled study // J Clin Psychiatry. – 2014. – Vol. 75 (4). – Pp. 362–368. – https://doi.org/10.4088/JCP.13m08433
  9. Jackson J.L., Houston J.S., Hanling S.R. et al. Clinical predictors of mental disorders among medical outpatients // Arch Intern Med. – 2001. – Vol. 161 (6). – Pp. 875–879. – https://doi.org/10.1001/achirt.1n6e1.6.875PMdbeu
  10. Andrews G., Slade T. The classification of anxiety disorders in ICD-10 and DSM-IV: a concordance analysis // Psychopathology. – 2002. – Vol. 35 (2-3). – Pp. 100–106. – https://doi.org/101.159/000065127PubMed
  11. Papadimitriou G.N., Linkowski P. Sleep disturbance in anxiety disorders // Int Rev Psychiatry. – 2005. – Vol. 17 (4). – Pp. 229–236. – https://doi.org/10d.o1080/095402605001045Pu2b4dMe
  12. Rickels K., Schweizer E. The spectrum of generalised anxiety in clinical practice: the role of short-term, intermittent treatment // Br J Psychiatry. – 1998. – Vol. 34. – Pp. 49–54.
  13. Stein D.J., Ahokas A., Jarema M., Avedisova A.S., Vavrusova L., Chaban O., Gruget C., Olivier V., Picarel-Blanchot F., de Bodinat C. Efficacy and safety of agomelatine (10 or 25 mg/day) in non-depressed out-patients with generalized anxiety disorder: A 12-week, double-blind, placebo-controlled study // Eur Neuropsychopharmacol. – 2017. – Vol. 27 (5). – Pp. 526–537. – https://doi.org/10.1016/j.euroneuro.2017.02.007
  14. Stein D.J., Khoo J.P., Ahokas A., Jarema M., Van Ameringen M., Vavrusova L., Hӧ schl C., Bauer M., Bitter I., Mosolov S.N., Olivier V., Matharan S., Picarel-Blanchot F., de Bodinat C. 12-week double-blind randomized multicenter study of efficacy and safety of agomelatine (25–50 mg/day) versus escitalopram (10–20 mg/day) in out-patients with severe generalized anxiety disorder // Eur Neuropsychopharmacol. – 2018. – Vol. 28 (8). – Pp. 970–979. – https://doi.org/10.1016/j.euroneuro.2018.05.006
  15. Norton P.J., Temple S.R., Pettit J.W. Suicidal ideation and anxiety disorders: elevated risk or artifact of comorbid depression? // J Behav Ther Exp Psychiatry. – 2008. – Vol. 39 (4). – Pp. 515–525. – https://doi.org/10.1016/j.jbtep.2007.10.010
  16. Haby M.M., Donnelly M., Corry J., Vos T. Cognitive behavioural therapy for depression, panic disorder and generalized anxiety disorder: A meta-regression of factors that may predict outcome // Aust N.Z.J. Psychiatry. – 2006. – Vol. 40. – Pp. 9–19.
  17. Kessler R.C., Brandenburg N., Lane M. et al. Rethinking the duration requirement for generalized anxiety disorder: evidence from the National Comorbidity Survey Replication // Psychol Med. – 2005. – Vol. 35 (7). – Pp. 1073–1082. – https://doi.org/10d.1o017/S003329150045783PbudMe
  18. Wittchen H.U. Generalized anxiety disorder: Prevalence, burden, and cost to society // Depress Anxiety. – 2002. – Vol. 16 (4). – Pp. 162–171. – https://doi.org/10.1002/da.10506PMuebd
  19. Doyle A.C., Pollack M.H. Establishment of remission criteria for anxiety disorders // J Clin Psychiatr. – 2003. – Vol. 64, suppl. 15. – Pp. 40–45.
  20. Baldwin D.S., Waldman S., Allgulander C. Evidence-based pharmacological treatment of generalized anxiety disorder // Int J Neuropsychopharmacol. – 2011. – Vol. 14. – Pp. 697–710. – https://doi.org/10.1017/s1461145710001434
  21. Tyrer P., Baldwin D. Generalised anxiety disorder // Lancet. – 2006. – Vol. 368. – Pp. 2156–2166. – https://doi.org/10.1016/s0140-6736(06)69865-6
  22. Незнанов Н.Г., Мартынихин И.А., Мосолов С.Н. Диагностика и терапия тревожных расстройств в Российской Федерации: результаты опроса врачей-психиатров // Современная терапия психических расстройств. – 2017. – № 2. – С. 2– https://doi.org/10.21265/PSYPH.2017.41.6437
  23. Генерализованное тревожное расстройство. Клинические рекомендации. Взрослые. Электронное издание. Минздрав РФ. – М., 2021. – 101 с. URL: https://cr.minzdrav.gov.ru/schema/457_2 (дата обращения 12.07.2024).
  24. Костюкова Е.Г. Генерализованное тревожное расстройство: основы диагностики, терапии и специфические для России проблемы // Современная терапия психически расстройств. – 2024. – № 2. – С. 23–31. – https://doi.org/10.21265/PSYPH.2024.31.31.003
  25. Мосолов С.Н., Алфимов П.В. Алгоритм биологической терапии генерализованного тревожного расстройства // Современная терапия психических расстройств. – 2015 № 2. – С. 24–28.
  26. Gould R.A., Otto M.W., Pollack M.H., Yap L. Cognitive behavioral and pharmacological treatment of generalized anxiety disorder: A preliminary meta-analysis // Behav Ther. – 1997. – Vol. 28. – Pp. 285–305. – https://doi.org/10.1016/s0005-7894(97)80048-2
  27. National Institute for Health and Care Excellence. Generalised anxiety disorder and panic disorder in adults: Management. – Available at: https://www. nice.org.uk/guidance/CG113 (accessed January 26, 2011).
  28. Slee A., Nazareth I., Bondaronek P., Liu Y., Cheng Z., Freemantle N. Pharmacological treatments for generalised anxiety disorder: A systematic review and network meta-analysis // Lancet. – 2019. – Vol. 393. – Pp. 768–777. – https://doi.org/10.1016/s0140-6736(18)31793-8
  29. Медведев В.Э., Котова О.В., Акарачкова Е.С., Беляев А.А., Паршакова Е.С. Генерализованное тревожное расстройство: анатомические и функциональные особе головного мозга. Авиандр — новые возможности терапии // Современная терапия в психиатрии и неврологии. – 2024. – № 2. – С. 14–20.
  30. Buoli M., Caldiroli A., Caletti E. et al. New approaches to the pharmacological management of generalized anxiety disorder // Expert Opin Pharmacother. – 2013. – Vol. 14 (2). – Pp. 175–184.
  31. Pollack M.H. Refractory generalized anxiety disorder // J Clin Psychiatry. – 2009. – Vol. 70, suppl. 2. – Pp. 32–38.
  32. Kapczinski F., Lima M.S., Souza J.S. et al. Antidepressants for generalized anxiety disorder // Cochrane Database Syst Rev. – 2003. – CD003592.
  33. Montgomery S.A., Kennedy S.H., Burrows G.D. et al. Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: A randomized, double-blind, placebo-controlled discontinuation study // Int Clin Psychopharmacol. – 2004. – Vol. 19. – Pp. 271–280.
  34. Аведисова А.С., Захарова К.В., Марачев М.П. Эффективность препарата агомелатин (Вальдоксан) при лечении пациентов с тревожной депрессией в рамках большого депрессивного расстройства. Результаты обсервационной программы «ДЖАЗ» // Психиатрия и психофармакотерапия имени П.Б. Ганнушкина. – 2013. – № 6. – С. 14–22.
  35. Мосолов С.Н. Хронобиологическая теория аффективных расстройств. – М.: АВАНПОРТ 2014. – 352 с.
  36. Петелин Д.С., Нийноя И.В., Сорокина О.В. и др. Терапия смешанного тревожного и депрессивного расстройства: результаты обсервационного исследования эффективности и переносимости агомелатина // Неврология, нейропсихиатрия, психосоматика. – 2021. – Т. 13 (6). – С. 48–54. – https://doi.org/10.14412/2074-2711-2021-6-48-54.
  37. Kennedy S.H., Avedisova A., Gimе nez-Montesinos N. et al. A placebo-controlled study of three agomelatine dose regimens (10 mg, 25 mg, 25–50 mg) in patients with major depressive disorder // European Neuropsychopharmacology. – 2014. – Т. 24, № 4. – С. 553–563.
  38. Гушанская Е.В., Фролова В.И., Медведев В.Э. Терапия тревожной депрессии (оп применения Вальдоксана) // Журнал психиатрии и психофармакотерапии. – 2015. – № 1. – С. 17–21.
  39. Медведев В.Э. Эффективность и переносимость современных антидепрессантов: результаты сетевых метаанализов и российский опыт // Журнал неврологии и психиатрии имени С.С. Корсакова. – 2018. – Vol. 118 (11). – С. 109–117 https://doi.org/10.17116/jnevro2018118111109
  40. Чернова Е.В., Кожечкина О.В., Тер-Исраелян А.Ю. и др. Эффективность и переносимо агомелатина (Вальдоксан) при терапии эндогенных депрессий в условия дневного стационара // Журнал неврологии и психиатрии имени С.С. Корсакова. – 2016. – № 10. C. 43–46. – https://doi.org/10.17116/jnevro201611610143-46
  41. Kennedy S.H., Avedisova A., Belaïdi C. et al. Sustained efficacy of agomelatine 10 mg, 25 mg, and 25–50 mg on depressive symptoms and functional outcomes in patients with major depressive disorder. A placebo-controlled study over 6 months // European Neuropsychopharmacology. – 2016. – Vol. 26, no. 2. – Pp. 378–389. – https://doi.org/10.1016/j.euroneuro.2015.09.006
  42. Медведев В.Э., Котова О.В., Палин А.В., Михеева О.В., Акарачкова Е.С. Агомелатин фармакологический профиль, возможности применения, преимущества // Неврология, нейропсихиатрия, психосоматика. – 2024. – T. 16 (4). – C. 103–110. – https://doi.org/10.14412/2074-2711-2024-4-103-110
  43. Stein D.J., Ahokasy A.A., de Bodinat Ch. Efficacy of agomelatine in generalized anxiety disorder: A randomized, double-blind, placebo-controlled study // J Clin Psychopharmacol. – 2008. – Vol. 28 (5). – Pp. 561–566. – https://doi.org/10.1097/JCP.0b013e318184ff5b
  44. Stein D.J., Ahokas A., Albarran C., Olivier V., Allgulander C. Agomelatine prevents relapse in generalized anxiety disorder: A 6-month randomized, double-blind, placebo-controlled discontinuation study // J Clin Psychiatry. – 2012. – Vol. 73 (7). – Pp. 1002–1008. – https://doi.org/10.4088/JCP.11m07493
  45. Stein D.J., Khoo J.P., Picarel-Blanchot F., Olivier V., van Ameringen M. Efficacy of agomelatine 25–50 mg for the treatment of anxious symptoms and functional impairment in generalized anxiety disorder: A meta-analysis of three placebo-controlled studies // Adv Ther. – 2021. – Vol. 38 (3). – Pp. 1567–1583. – https://doi.org/10.1007/s12325-020-01583-9
  46. Slee A., Nazareth I., Bondaronek P., Liu Y., Cheng Z., Freemantle N. Pharmacological treatments for generalised anxiety disorder: A systematic review and network meta-analysis // Lancet. – 2019. Vol. 393 (10173). – Pp. 768–777. – https://doi.org/10.1016/S0140-6736(18)31793-8
  47. Quilichini J.B., Revet A., Garcia P., Bouquiе R., Hamard J., Yrondi A., Montastruc F. Comparative effects of 15 antidepressants on the risk of withdrawal syndrome: A real-world study using the WHO pharmacovigilance database // J Affect Disord. – 2022. – Vol. 297. – Pp. 189–193. – https://doi.org/10.1016/j.jad.2021.10.041
  48. Хасанова А.К., Мосолов С.Н. Синдромом отмены приема антидепрессантов (алгор профилактики и коррекции) // Современная терапия психических расстройств. – 2023. – № 2. – С. 37–47. – https://doi.org/10.21265/PSYPH.2023.15.79.005
  49. Montejo A.L., Prieto N., de Alarcоn R., Casado-Espada N., de la Iglesia J., Montejo L. Management strategies for antidepressant-related sexual dysfunction: A clinical approach // J Clin Med. – 2019. – Vol. 8 (10). – Art. 1640. – https://doi.org/10.3390/jcm8101640
  50. Салахова А.И., Ягубов М.И. Сексуальная дисфункция при применении антидепрессантов у пациентов с тревожными и депрессивными расстройствами (алгоритм ведения и коррекции) // Современная терапия психических расстройств. – 2024. – № 2. – С. 56–67. – https://doi.org/10.21265/PSYPH.2024.31.31.006

Downloads

Download data is not yet available.